FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2023/02/050087 [Registered on: 26/02/2023] Trial Registered Prospectively
Last Modified On: 23/02/2023
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Surgical/Anesthesia 
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   TO COMPARE 0.5% LEVOBUPIVACAINE HEAVY AND 0.75% ROPIVACAINE HEAVY FOR SPINAL ANAESTHESIA IN LOWER LIMB ORTHOPAEDIC SURGERIES 
Scientific Title of Study   A COMPARATIVE STUDY OF 0.5% HYPERBARIC LEVOBUPIVACAINE AND 0.75% HYPERBARIC ROPIVACAINE FOR SPINAL ANAESTHESIA IN LOWER LIMB ORTHOPAEDIC SURGERIES 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  NAVANITHA SHAINE 
Designation  JUNIOR RESIDENT 
Affiliation  JSS Academy of Higher Education 
Address  Department of Anaesthesiology JSS Hospital Mysore Karnataka India 570004

Mysore
KARNATAKA
570004
India 
Phone  9620331916  
Fax    
Email  navanitha.shaine@yahoo.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr BP Manjula 
Designation  PROFESSOR 
Affiliation  JSS Academy of Higher Education 
Address  Department of Anaesthesiology JSS Hospital Mysore Karnataka India 570004

Mysore
KARNATAKA
570004
India 
Phone  9845501226  
Fax    
Email  bpmanjula5@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr BP Manjula 
Designation  PROFESSOR 
Affiliation  JSS Academy of Higher Education 
Address  Department of Anaesthesiology JSS Hospital Mysore Karnataka India 570004

Mysore
KARNATAKA
570004
India 
Phone  9845501226  
Fax    
Email  bpmanjula5@gmail.com  
 
Source of Monetary or Material Support  
JSS MEDICAL COLLEGE AND HOSPITAL 
 
Primary Sponsor  
Name  JSSAHER 
Address  JSS Medical College and Hospital, Mysore, Karnataka,India, 570004 
Type of Sponsor  Private medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr NAVANITHA SHAINE  JSS MEDICAL COLLEGE AND HOSPITAL  Patients of Orthopaedics posted for lower limb surgeries under spinal anaesthesia, 3rd floor OT complex, Agrahara, JSS Hospital, Mysore, Karnataka,India, 570004
Mysore
KARNATAKA 
9620331916

navanitha.shaine@yahoo.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
INSTITUTIONAL ETHICS COMMITTEE  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: M958||Other specified acquired deformities of musculoskeletal system,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Hyperbaric Levobupivacaine 0.5%   With the patient in sitting position, lumbar puncture will be performed with the midline approach at the L2-L3 or L3-4 interspace using 25G Quinke’s Spinal Needle. Correct needle positioning will be confirmed with free flow of cerebrospinal fluid and 3 ml of Hyperbaric Levobupivacaine 0.5% will be injected intrathecally slowly (injection speed: 0.2mL/sec) without further aspiration maneuvers.  
Comparator Agent  Hyperbaric Ropivacaine 0.75%  With the patient in sitting position, lumbar puncture will be performed with the midline approach at the L2-L3 or L3-4 interspace using 25G Quinke’s Spinal Needle. Correct needle positioning will be confirmed with free flow of cerebrospinal fluid and 3 ml of Hyperbaric Ropivacaine will be injected intrathecally slowly (injection speed: 0.2mL/sec) without further aspiration maneuvers.  
Intervention  Sub Arachnoid Block  On the day of surgery Intravenous (IV) access will be secured. In the operation theater standard monitoring devices will be attached, including noninvasive arterial blood pressure, ECG, and oxygen saturation probe and baseline readings will be recorded. With the patient in sitting position, lumbar puncture will be performed with the midline approach at the L2-L3 or L3-4 interspace using 25G Quinke’s Spinal Needle. Correct needle positioning will be confirmed with free flow of cerebrospinal fluid and 3 ml of study drug will be injected intrathecally slowly (injection speed: 0.2mL/sec) without further aspiration maneuvers.  
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  ASA physical status I – II patients of either sex between age 18- 60 years. Patients undergoing lower limb orthopaedic surgeries.
 
 
ExclusionCriteria 
Details  1. Patient refusal for the procedure.
2. Spinal anomalies.
3. Any contraindications to spinal anaesthesia such as local infection at site of injection, allergy to the drugs, raised intracranial pressure, deranged coagulation profile.
4. ASA physical status III and above.
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Other 
Blinding/Masking   Investigator Blinded 
Primary Outcome  
Outcome  TimePoints 
1. To compare the efficacy of sensory and motor blockade of 0.5% Hyperbaric Levobupivacaine and 0.75% Hyperbaric Ropivacaine in spinal anaesthesia for lower limb orthopaedic surgeries.  Assessments of sensory and motor block will be continued at 30 min intervals thereafter until complete motor and sensory blocks regression.  
 
Secondary Outcome  
Outcome  TimePoints 
1.Intraoperative hemodynamic changes
2.Time for first post operative rescue analgesia requirement.
3.Incidence of adverse events such as nausea and vomiting in the postoperative period.
 
Assessment will be continued until complete motor and sensory block regression. 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   01/03/2023 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   Not yet 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Following approval from the Institutional Ethical Committee, informed consent will be taken from 60 patients satisfying the inclusion criteria and they will be randomly allocated by single blinding technique into 2 groups namely Group L (0.5% Hyperbaric Levobupivacaine) and Group R (0.75% Hyperbaric Ropivacaine). 

Total number of patients will be 60, with 30 patients in each group.

1. Group L (n=30) will receive 0.5% Hyperbaric Levobupivacaine injected intrathecally.

2. Group R (n=30) will receive 0.75% Hyperbaric Ropivacaine injected intrathecally.

Procedure:

All patients will be admitted before the surgery and pre anaesthetic evaluation will be done. Fasting of 6 hours for solids and 2 hours for clear liquids will be ensured.

After obtaining written informed consent, patients of ASA I–II of either gender, undergoing lower limb orthopaedic surgery in whom spinal anesthesia is indicated, will be included in the study. Patients with contraindication to spinal anaesthesia, allergy to local anaesthetics, spinal deformities, bleeding disorders and ASA III and above will not be included.

On the day of surgery Intravenous (IV) access will be secured. In the operation theater standard monitoring devices will be attached, including noninvasive arterial blood pressure, ECG, and oxygen saturation probe and baseline readings will be recorded.

With the patient in sitting position, lumbar puncture will be performed with the midline approach at the L2-L3 or L3-4 interspace using 25G Quinke’s Spinal Needle. Correct needle positioning will be confirmed with free flow of cerebrospinal fluid and 3 ml of study drug will be injected intrathecally slowly (injection speed: 0.2mL/sec) without further aspiration maneuvers. The patient will be turned to supine position immediately after the injection, the time of which is defined as ‘zero’. Patient will receive IV Inj. Ondansetron 4mg and Inj. Midazolam 1mg.

Thereafter, the investigator will assess the following.

       Sensory blockade-

·       Sensory blockade onset time

·       Maximum height of sensory block

·       Sensory blockade regression time

·       Total sensory block duration

       Motor blockade

·       Motor blockade onset time

·       Motor blockade regression time

·       Total motor blockade duration

Sensory block will be assessed by analgesia to pinprick in anterior axillary line every minute till sensory block is achieved at T10. The sensory block starting time will be taken as the time taken for the block to reach T10. The sensory block will be assessed every 5 minutes till the maximum height of sensory block is achieved and will be recorded. 2 segment regression time i.e the time taken for the sensory block to regress 2 segments from the maximum height attained will be noted and taken as sensory block regression time.

The degree of motor block will be assessed using modified Bromage scale 

 Motor block onset time will be time when Bromage Scale 3 occurred and motor block regression time will be when return to Bromage Scale 1 occurs. Total duration of motor block is the period between these 2 times.

The heart rate and arterial pressure and peripheral oxygen saturation will be recorded at time 0 and then at 5 min intervals for the first 30 mins and then every 10 mins till end of surgery.

Assessments of sensory and motor block will be continued at 30 min intervals thereafter until complete motor and sensory blocks regression.

Hypotension (20% or more decrease in mean arterial blood pressure [MAP] from the baseline value) will be treated with boluses of IV Mephentermine (6 mg) and crystalloid infusion until the normotensive state is achieved. Bradycardia (20% or more decrease in heart rate [HR] from the baseline value) will be treated with 0.6 mg IV atropine.

In the post operative period, the first time the patient complains of pain at the operated site will be recorded and this will be taken as time of end of sensory block. The time duration between onset of block at T10 and the feeling of first post operative pain will be taken as total duration of sensory block.

Patient will be observed for any side effects such as nausea and vomiting in the post operative period.

 
Close